Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

"The Timing of Venous Thromboembolism in Ovarian Cancer patients. A Nationwide Danish Cohort Study"

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Harvard

Kahr, HS, Christiansen, OB, Juul Riddersholm, S, Gade, IL, Torp-Pedersen, C, Knudsen, A & Thorlacius-Ussing, O 2021, '"The Timing of Venous Thromboembolism in Ovarian Cancer patients. A Nationwide Danish Cohort Study"', Journal of thrombosis and haemostasis : JTH, bind 19, nr. 4, s. 992-1000. https://doi.org/10.1111/jth.15235

APA

Kahr, H. S., Christiansen, O. B., Juul Riddersholm, S., Gade, I. L., Torp-Pedersen, C., Knudsen, A., & Thorlacius-Ussing, O. (2021). "The Timing of Venous Thromboembolism in Ovarian Cancer patients. A Nationwide Danish Cohort Study". Journal of thrombosis and haemostasis : JTH, 19(4), 992-1000. https://doi.org/10.1111/jth.15235

CBE

MLA

Vancouver

Author

Kahr, Henriette Strøm ; Christiansen, Ole Bjarne ; Juul Riddersholm, Signe ; Gade, Inger Lise ; Torp-Pedersen, Christian ; Knudsen, Aage ; Thorlacius-Ussing, Ole. / "The Timing of Venous Thromboembolism in Ovarian Cancer patients. A Nationwide Danish Cohort Study". I: Journal of thrombosis and haemostasis : JTH. 2021 ; Bind 19, Nr. 4. s. 992-1000.

Bibtex

@article{2edac2a3561645aca4e36c928ac573bf,
title = "{"}The Timing of Venous Thromboembolism in Ovarian Cancer patients. A Nationwide Danish Cohort Study{"}",
abstract = "Background and aim: Venous thromboembolism (VTE) is associated with excess mortality and morbidity in cancer, and is influenced by patient-, tumor-, and treatment-related factors. We aimed to investigate the impact of such factors in a national cohort of patients with epithelial ovarian cancer (EOC). Methods: Patients in the Danish Gynecologic Cancer Database (DGCD) with EOC from 2005 to 2014 were followed from time of diagnosis to VTE, or censoring. Surgery, chemotherapy, and vascular epithelial growth factor (VEGF)-inhibitors were included as time-varying exposures in Cox proportional hazard regression models. Results: A total of 551 VTE events were registered in 4991 EOC patients. Median follow-up time was 2.9 years. The 2-year cumulative incidence of VTE was 7.2%. Patients were at highest risk during the first year after EOC diagnosis. Previous VTE was associated with a hazard ratio (HR) of 3.26 (95% confidence interval [CI] 2.42–4.39). Exposure to major pelvic surgery was associated with a HR of 3.21 (95% CI 2.29–4.50). Exposure to chemotherapy or (VEGF)-inhibitors were associated with HRs of 1.91 (95% CI 1.56–2.33) and 1.05 (95% CI 0.57–1.93), respectively. Hazard ratios for patients with clear cell histopathology was 1.46 (95% CI 0.97–2.20) and 2.42 for International Federation of Gynaecology and Obstetrics stage III--IV (95% CI 1.93–3.03). Conclusions: EOC is associated with a high risk of VTE, particularly within the first year after diagnosis. Major pelvic surgery and chemotherapy were strongly associated with VTE. Person-related risk factors were increasing age and previous VTE. Advanced stage was an independent tumor-related risk factor. These findings support the indication for thrombosis prophylaxis during chemotherapy.",
keywords = "deep vein thrombosis, epithelial ovarian cancer, ovarian cancer, pulmonary embolism, venous thromboembolism, venous thromboprophylaxis",
author = "Kahr, {Henriette Str{\o}m} and Christiansen, {Ole Bjarne} and {Juul Riddersholm}, Signe and Gade, {Inger Lise} and Christian Torp-Pedersen and Aage Knudsen and Ole Thorlacius-Ussing",
note = "{\textcopyright} 2021 International Society on Thrombosis and Haemostasis.",
year = "2021",
month = apr,
doi = "10.1111/jth.15235",
language = "English",
volume = "19",
pages = "992--1000",
journal = "Journal of Thrombosis and Haemostasis",
issn = "1538-7933",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "4",

}

RIS

TY - JOUR

T1 - "The Timing of Venous Thromboembolism in Ovarian Cancer patients. A Nationwide Danish Cohort Study"

AU - Kahr, Henriette Strøm

AU - Christiansen, Ole Bjarne

AU - Juul Riddersholm, Signe

AU - Gade, Inger Lise

AU - Torp-Pedersen, Christian

AU - Knudsen, Aage

AU - Thorlacius-Ussing, Ole

N1 - © 2021 International Society on Thrombosis and Haemostasis.

PY - 2021/4

Y1 - 2021/4

N2 - Background and aim: Venous thromboembolism (VTE) is associated with excess mortality and morbidity in cancer, and is influenced by patient-, tumor-, and treatment-related factors. We aimed to investigate the impact of such factors in a national cohort of patients with epithelial ovarian cancer (EOC). Methods: Patients in the Danish Gynecologic Cancer Database (DGCD) with EOC from 2005 to 2014 were followed from time of diagnosis to VTE, or censoring. Surgery, chemotherapy, and vascular epithelial growth factor (VEGF)-inhibitors were included as time-varying exposures in Cox proportional hazard regression models. Results: A total of 551 VTE events were registered in 4991 EOC patients. Median follow-up time was 2.9 years. The 2-year cumulative incidence of VTE was 7.2%. Patients were at highest risk during the first year after EOC diagnosis. Previous VTE was associated with a hazard ratio (HR) of 3.26 (95% confidence interval [CI] 2.42–4.39). Exposure to major pelvic surgery was associated with a HR of 3.21 (95% CI 2.29–4.50). Exposure to chemotherapy or (VEGF)-inhibitors were associated with HRs of 1.91 (95% CI 1.56–2.33) and 1.05 (95% CI 0.57–1.93), respectively. Hazard ratios for patients with clear cell histopathology was 1.46 (95% CI 0.97–2.20) and 2.42 for International Federation of Gynaecology and Obstetrics stage III--IV (95% CI 1.93–3.03). Conclusions: EOC is associated with a high risk of VTE, particularly within the first year after diagnosis. Major pelvic surgery and chemotherapy were strongly associated with VTE. Person-related risk factors were increasing age and previous VTE. Advanced stage was an independent tumor-related risk factor. These findings support the indication for thrombosis prophylaxis during chemotherapy.

AB - Background and aim: Venous thromboembolism (VTE) is associated with excess mortality and morbidity in cancer, and is influenced by patient-, tumor-, and treatment-related factors. We aimed to investigate the impact of such factors in a national cohort of patients with epithelial ovarian cancer (EOC). Methods: Patients in the Danish Gynecologic Cancer Database (DGCD) with EOC from 2005 to 2014 were followed from time of diagnosis to VTE, or censoring. Surgery, chemotherapy, and vascular epithelial growth factor (VEGF)-inhibitors were included as time-varying exposures in Cox proportional hazard regression models. Results: A total of 551 VTE events were registered in 4991 EOC patients. Median follow-up time was 2.9 years. The 2-year cumulative incidence of VTE was 7.2%. Patients were at highest risk during the first year after EOC diagnosis. Previous VTE was associated with a hazard ratio (HR) of 3.26 (95% confidence interval [CI] 2.42–4.39). Exposure to major pelvic surgery was associated with a HR of 3.21 (95% CI 2.29–4.50). Exposure to chemotherapy or (VEGF)-inhibitors were associated with HRs of 1.91 (95% CI 1.56–2.33) and 1.05 (95% CI 0.57–1.93), respectively. Hazard ratios for patients with clear cell histopathology was 1.46 (95% CI 0.97–2.20) and 2.42 for International Federation of Gynaecology and Obstetrics stage III--IV (95% CI 1.93–3.03). Conclusions: EOC is associated with a high risk of VTE, particularly within the first year after diagnosis. Major pelvic surgery and chemotherapy were strongly associated with VTE. Person-related risk factors were increasing age and previous VTE. Advanced stage was an independent tumor-related risk factor. These findings support the indication for thrombosis prophylaxis during chemotherapy.

KW - deep vein thrombosis

KW - epithelial ovarian cancer

KW - ovarian cancer

KW - pulmonary embolism

KW - venous thromboembolism

KW - venous thromboprophylaxis

UR - http://www.scopus.com/inward/record.url?scp=85100674487&partnerID=8YFLogxK

U2 - 10.1111/jth.15235

DO - 10.1111/jth.15235

M3 - Journal article

C2 - 33420762

VL - 19

SP - 992

EP - 1000

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

SN - 1538-7933

IS - 4

ER -

ID: 61787298